BioPharma Resources

Drug Trial Radar · NCT07672574

Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers

An Open-label, Two-part Trial to Assess the Mass-balance Recovery, Metabolite Profile, Metabolite Identification and Absolute Bioavailability of [14C] Ontunisertib in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Sep 9, 2026

Primary completion

Jan 31, 2027

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Agomab Spain S.L.U.Industry
Sponsor type
Industry
First posted
Jun 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 30 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open, two-part study in healthy male volunteers, aged 30-65 years. This trial aims to understand how the human body absorbs, distributes, metabolizes and eliminates ontunisertib after a single oral dose of radiolabelled test medicine (\[14C\]ontunisertib) and determine the routes and rates of elimination of the test medicine.

Conditions

  • Fibrostenotic Crohn's Disease

Interventions

  • OntunisertibDrug

    Oral capsule

  • [14C]ontunisertibDrug

    IV infusion

  • [14C]ontunisertibDrug

    Oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute bioavailability of ontunisertib following oral and IV administrationTime frame: Through study completion, an average of 8 days
  2. Cumulative amount of total radioactivity excreted in urine and fecesTime frame: Through study completion, an average of 10 days
  3. Chemical structure of each metabolite accounting for ≥10% of circulating total radioactivity and Metabolite profiling accounting for >80% of total radioactivity recovered in urine and/or fecesTime frame: Through study completion, an average of 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences Limited

    Nottingham, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.